Hodgkin Lymphoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The Hodgkin lymphoma treatment market is expected to register a CAGR of 12.5% during the forecast period (2022-2027).

The emergence of the COVID-19 pandemic affected the healthcare industry in many ways such as a reduction in footfall in the hospitals and clinics, cancellation or postponement of treatment or diagnostic procedures, disruption in the pharmaceutical supply chain, and others, which have had its impact on the studied market. In November 2020, a research study published titled, "COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study" stated that the number of comorbidities, active cancer, and worse performance status was associated with increased 30-day mortality due to the pandemic. Hence, lockdown and utilization of resources against COVID had adversely affected the market growth. However, the market would increase in the long term. For instance, in November 2021, a research study published titled "COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review" stated that patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Chemotherapy treatment combined with rituximab (widely available immunotherapy against B-lymphocytes) is the current standard upfront treatment for most histologies. Hence, the increasing prevalence of Hodgkin lymphoma (HL) is expected to increase the demand for treatment which would increase the market growth in the long term.

The growing burden of Hodgkin lymphoma and increasing awareness about Hodgkin Lymphoma (HL) are key factors in the market growth. The American Cancer Society’s estimates for Hodgkin lymphoma in the United States for 2022 are about 8,540 new cases (4,570 in males and 3,970 in females) and about 920 deaths (550 males and 370 females). Both children and adults can develop Hodgkin lymphoma, but it's most common in early adulthood (especially in a person’s 20s). The risk of Hodgkin lymphoma rises again in late adulthood (after age 55). Overall, the average age of people when they are diagnosed is 39. Hodgkin lymphoma is rare in children younger than 5 years old. But it's the most common cancer diagnosed in adolescents ages 15 to 19 years. Various research studies on the efficacy of better treatments have been conducted and are increasing the awareness related to the diseases and their treatments. For instance, in June 2022, a research study was published titled "Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463)" stated that the anti-CD30 antibody-drug conjugate, Brentuximab vedotin (Bv) is approved for adults with advanced-stage HL but its use has not been established in children or adolescents. Brentuximab vedotin with AVE-PC in a dose-intensive regimen has superior efficacy to ABVE-PC for pediatric patients with high-risk HL. A 59% risk reduction in EFS was achieved with no increase in toxicity. Hence, such studies increase the market growth by providing better treatment options thus increasing demand. However, adverse long-term side effects and the high cost of treatment are expected to restrain the growth of the Hodgkin lymphoma treatment market.

Scope of the Report

As per the scope of the report, Hodgkin's lymphoma (HL) is a type of lymphoma in which cancer originates from lymphocytes. The Hodgkin lymphoma treatment market is segmented by treatment type (chemotherapy, radiotherapy, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Radiotherapy Segment is Expected to Register a Significant Growth over the Forecast Period

Radiotherapy is a well-established technique for destroying Hodgkin’s disease cells by using high-energy beams or particles to kill cancer cells and may be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. For classical Hodgkin’s disease, radiotherapy is often given after chemotherapy, especially when there is a large or bulky tumor mass. In June 2020, a research study published titled "Radiation Therapy for Advanced-Stage Hodgkin Lymphoma" stated that according to the American Cancer Society, Hodgkin lymphoma (HL) is a rare disease, with an estimated 8110 new diagnoses and 1000 deaths from HL in 2019. In recent years, there have been numerous advances in systemic therapies, including checkpoint inhibitors and brentuximab vedotin (Bv), an antibody-drug conjugate targeting CD30. Although exciting, these new drugs come with high price tags and their potential synergies with RT remain relatively unknown.

A similar research study that was published in August 2020 under the title "Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management" stated that patients with early-stage disease are typically treated with combined modality strategies using condensed courses of combination chemotherapy, followed by involved-field radiation therapy (radiotherapy). RT fields have decreased in size, and technology has improved over time with the advent of improved treatment planning techniques and PET imaging. The use of CT-based simulation, deep-inspiration breath-hold technique, and daily image guidance during RT have allowed for more conformal and precise treatments with improved protection of normal tissues. Hence, such studies will increase the market share in the upcoming period. Hence, with the rising burden of cancer, along with increasing awareness about Hodgkin's lymphoma, the market is expected to grow in the forecast period.

To understand key trends, Download Sample Report